Were the GLP-1 receptor agonist drug s apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.
Taking longer between first and last meals of the day may indirectly improve metabolic health for some heart failure patients, propose researchers from preliminary findings that go against intermittent fasting.
Women with obesity experience greater menopausal symptoms but substantially less relief from hormone therapy than women without obesity, according to a study.
Compared with naltrexone/bupropion for weight loss, semaglutide and liraglutide were associated with a higher risk for three adverse gastrointestinal outcomes.